Condition (MeSH)
Crigler-Najjar Syndrome
ClinicalTrials.gov lists 13 trials for Crigler-Najjar Syndrome or a narrower condition beneath it. Cellaion SA has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 13 trials are tagged with Crigler-Najjar Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Crigler-Najjar Syndrome trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 2 |
| 2022 | 1 |
| 2018 | 2 |
| 2017 | 2 |
| 2014 | 2 |
| 2013 | 1 |
| 2012 | 1 |
| 2011 | 1 |
| 2003 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Crigler-Najjar Syndrome trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 1 |
| Not applicable | 3 |
| Observational | 5 |
How many Crigler-Najjar Syndrome trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Completed | 6 |
| Terminated | 3 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Crigler-Najjar Syndrome trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Cellaion SA | 3 |
| Audentes Therapeutics | 2 |
| Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare | 1 |
Which drugs are being tested for Crigler-Najjar Syndrome? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Imlifidase | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| GNT0003 | 2 |
| Orlistat 60 | 1 |
| human hepatocyte transplantation | 1 |
| GT-UGT1A1-AAV8-02 | 1 |
| Blood sample for immunology | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Crigler-Najjar Syndrome? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Gene Therapy in Patients with the Crigler-Najjar Syndrome. | The New England journal of medicine | 2023 | Yes |
| Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. | Pediatrics | 2003 | Yes |
| Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. | The New England journal of medicine | 1998 | Yes |
| Vigintiphobia revisited. | Pediatrics | 2005 | No |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Crigler-Najjar syndrome | Prevalence at birth | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Crigler-Najjar syndrome | Prevalence at birth | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Crigler-Najjar syndrome | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| Crigler-Najjar syndrome | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Crigler-Najjar syndrome | Prevalence at birth | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Crigler-Najjar syndrome | 205 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Crigler-Najjar syndrome | 205 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.